Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Qianli Zhu, Jiaqian Miao, and Danni Xu contributed equally to this work. Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. Supporting Information Filename Description adma74178-sup-0001-SuppMat.docx4.9 MB Supporting File: adma74178-sup-0001-SuppMat.docx.
Abstract Background: Batroxobin, a defibrinogenating agent used as an adjunctive therapy for sudden sensorineural hearing loss (SSNHL), has an incompletely characterized cardiovascular safety profile. Cases: We report three male patients with SSNHL who developed acute myocardial infarction (AMI) after batroxobin therapy. All three showed a precipitous fibrinogen decline (nadir: 0.48–0.75 g/L). AMI was diagnosed approximately 24–48 h after the final batroxobin dose.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.